drugset / Trial / NCT00614939

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939

Phase 3 Completed 572 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.

Timeline

Start
2008-01
Primary completion
2009-06
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 2.5 mg Oral